The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 18, 2023
Filed:
Sep. 04, 2018
Inserm (Institut National DE LA Sante ET DE LA Recherche Medicale), Paris, FR;
Universite Paris Descartes, Paris, FR;
Fondation Imagine, Paris, FR;
Assistance Publique-hopitaux DE Paris (Aphp), Paris, FR;
Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;
Universite Grenoble Alpes, Saint Martin d'Heres, FR;
Commissariat a L'energie Atomique ET Aux Energies Alternatives, Paris, FR;
Universite DE Bourgogne, Dijon, FR;
Zakia Belaid-Choucair, Paris, FR;
Olivier Hermine, Paris, FR;
Carmen Garrido-Fleury, Dijon, FR;
Claude Cochet, Grenoble, FR;
Odile Filhol-Cochet, Grenoble, FR;
Renaud Seigneuric, Dijon, FR;
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris, FR;
UNIVERSITÉ PARIS CITÉ, Paris, FR;
FONDATION IMAGINE, Paris, FR;
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP), Paris, FR;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris, FR;
UNIVERSITE GRENOBLE ALPES, Saint-Martin-d'Hères, FR;
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, Paris, FR;
UNIVERSITE DE BOURGOGNE, Dijon, FR;
Abstract
The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.